Commentary

Video

Unveiling the Latest in HER2+ Breast Cancer and Beyond With Drs Sara Hurvitz and Neil Iyengar

Author(s):

Chandler Park, MD, MSc, FACP,Sara A. Hurvitz, MD, FACP

Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Related Videos
5 experts are featured in this series
Odzer on ERBB2 Copy Number Ratio as a Predictive Biomarker in HER2+ Breast Cancer
Jian Zhang, MD
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
2 experts are featured in this series.
2 experts are featured in this series.
Gustavo Werutsky, MD, PhD, medical oncologist, Breast Cancer Program, Hospital Moinhos de Vento; investigator, Oncology Research Centre, Hospital São Lucas PUCRS University
Related Content
First-Line Tislelizumab Plus Chemo in ESCC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
January 23rd 2025

First-Line Tislelizumab Plus Chemo Elicits Deep Responses Linked to OS Benefits in ESCC

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

Top Abstracts to be Shared at 2025 ASCO GI | Image Credit: © peterschreiber.media – stock.adobe.com
January 22nd 2025

Oncology Experts Preview Top Abstracts to be Shared at 2025 ASCO GI

James J. Harding, MD, director, Early Drug Development, Memorial Sloan Kettering Cancer Center
December 30th 2024

FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer

Image Credit: © Sebastian Kaulitzki – stock.adobe.com
January 21st 2025

Everolimus Plus Lanreotide Extends PFS in Advanced GEP-NETs

David Rimm, MD, PhD, Yale Cancer Center
January 21st 2025

Quantitative IHC Assays May Bridge Gaps in Breast Cancer IHC Test Concordance